Novel uses for statins in surgical patients

International Journal of Surgery

Volumn 7, Issue 4, 2009, Pages 285-290

  Gajendragadkar, P R ^a   Cooper, D G ^a   Walsh, S R ^a   Tang, T Y ^a   Boyle, J R ^a   Hayes, P D ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Review; Statins; Surgery; Vascular

Indexed keywords

ATORVASTATIN; BISOPROLOL; C REACTIVE PROTEIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FIBRINOGEN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 10; INTERLEUKIN 6; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MATRIX METALLOPROTEINASE; MEVINOLIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TROPONIN;

ACUTE CORONARY SYNDROME; ACUTE PANCREATITIS; ANEURYSM; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; CARDIOVASCULAR SURGERY; CAROTID ARTERY DISEASE; CAROTID ENDARTERECTOMY; DRUG MEGADOSE; DYSLIPIDEMIA; FIBRINOLYSIS; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; INFLAMMATION; MORTALITY; NONHUMAN; PERIPHERAL VASCULAR DISEASE; PERITONEUM ADHESION; PERITONITIS; PLEIOTROPY; POSTOPERATIVE ADHESION; PREOPERATIVE CARE; PRIORITY JOURNAL; RAT; RENAL PROTECTION; REVIEW; RISK REDUCTION; SEPSIS; STROKE; SUBARACHNOID HEMORRHAGE; TRANSIENT ISCHEMIC ATTACK; VASODILATATION;

ANIMALS; CARDIOVASCULAR DISEASES; CEREBROVASCULAR DISORDERS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; DRUG TOXICITY; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; PERIOPERATIVE CARE; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; RATS; RISK REDUCTION BEHAVIOR; SURGICAL PROCEDURES, OPERATIVE; TREATMENT OUTCOME; VASCULAR SURGICAL PROCEDURES;

EID: 68949186465     PISSN: 17439191     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijsu.2009.04.016     Document Type: Review

References (87)

1. Kapur N.K., and Musunuru K. Clinical efficacy and safety of statins in managing cardiovascular risk. Vasc Health Risk Manag 4 2 (2008) 341-353
2. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). Lancet 344 8934 (1994) 1383-1389
3. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 9326 (2002) 7-22
4. Werner N., Nickenig G., and Laufs U. Pleiotropic effects of HMG-CoA reductase inhibitors. Basic Res Cardiol 97 2 (2002) 105-116
5. Wolfrum S., Jensen K.S., and Liao J.K. Endothelium-dependent effects of statins. Arterioscler Thromb Vasc Biol 23 5 (2003) 729-736
6. Lazar H.L., Bao Y., Zhang Y., and Bernard S.A. Pretreatment with statins enhances myocardial protection during coronary revascularization. J Thorac Cardiovasc Surg 125 5 (2003) 1037-1042
7. Vlachopoulos C., Aznaouridis K., Dagre A., Vasiliadou C., Masoura C., Stefanadi E., et al. Protective effect of atorvastatin on acute systemic inflammation-induced endothelial dysfunction in hypercholesterolaemic subjects. Eur Heart J 28 17 (2007) 2102-2109
8. Sander K., Hof U., Poppert H., Conrad B., and Sander D. Improved cerebral vasoreactivity after statin administration in healthy adults. J Neuroimaging 15 3 (2005) 266-270
9. Kumar V., Abbas A., and Fausto N. Hemodynamic disorders, thrombosis, and shock. Robbins and Cotran: pathologic basis of disease (2005), Elsevier Saunders
10. Eto M., and Luscher T.F. Modulation of coagulation and fibrinolytic pathways by statins. Endothelium 10 1 (2003) 35-41
11. Rosenson R.S., and Tangney C.C. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA 279 20 (1998) 1643-1650
12. Relou I.A., Hackeng C.M., Akkerman J.W., and Malle E. Low-density lipoprotein and its effect on human blood platelets. Cell Mol Life Sci 60 5 (2003) 961-971
13. Balk E.M., Lau J., Goudas L.C., Jordan H.S., Kupelnick B., Kim L.U., et al. Effects of statins on nonlipid serum markers associated with cardiovascular disease: a systematic review. Ann Intern Med 139 8 (2003) 670-682
14. Paraskevas K.I., Baker D.M., Vrentzos G.E., and Mikhailidis D.P. The role of fibrinogen and fibrinolysis in peripheral arterial disease. Thromb Res 122 1 (2008) 1-12
15. Almeida J.L., Sampietre S.N., Mendonca Coelho A.M., Trindade Molan N.A., Machado M.C., Monteiro da Cunha J.E., et al. Statin pretreatment in experimental acute pancreatitis. JOP 9 4 (2008) 431-439
16. Hirschfield G.M., and Pepys M.B. C-reactive protein and cardiovascular disease: new insights from an old molecule. QJM 96 11 (2003) 793-807
17. Li J.J., Chen M.Z., Chen X., and Fang C.H. Rapid effects of simvastatin on lipid profile and C-reactive protein in patients with hypercholesterolemia. Clin Cardiol 26 10 (2003) 472-476
18. Steiner S., Speidl W.S., Pleiner J., Seidinger D., Zorn G., Kaun C., et al. Simvastatin blunts endotoxin-induced tissue factor in vivo. Circulation 111 14 (2005) 1841-1846
19. Li J.J., Li Y.S., Chen J., and Yang J.Q. Rebound phenomenon of inflammatory response may be a major mechanism responsible for increased cardiovascular events after abrupt cessation of statin therapy. Med Hypotheses 66 6 (2006) 1199-1204
20. Arthurs Z.M., Andersen C., Starnes B.W., Sohn V.Y., Mullenix P.S., and Perry J. A prospective evaluation of C-reactive protein in the progression of carotid artery stenosis. J Vasc Surg 47 4 (2008) 744-750 [discussion: 751]
21. Albert M.A., Danielson E., Rifai N., and Ridker P.M. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 286 1 (2001) 64-70
22. Ridker P.M., Danielson E., Fonseca F.A., Genest J., Gotto A.M., Kastelein J.J., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359 (2008) 2195-2207
23. Cohen M.C., and Aretz T.H. Histological analysis of coronary artery lesions in fatal postoperative myocardial infarction. Cardiovasc Pathol 8 3 (1999) 133-139
24. Shiomi M., Ito T., Hirouchi Y., and Enomoto M. Stability of atheromatous plaque affected by lesional composition: study of WHHL rabbits treated with statins. Ann N Y Acad Sci 947 (2001) 419-423
25. Shiomi M., Ito T., Tsukada T., Yata T., Watanabe Y., Tsujita Y., et al. Reduction of serum cholesterol levels alters lesional composition of atherosclerotic plaques. Effect of pravastatin sodium on atherosclerosis in mature WHHL rabbits. Arterioscler Thromb Vasc Biol 15 11 (1995) 1938-1944
26. Crisby M., Nordin-Fredriksson G., Shah P.K., Yano J., Zhu J., and Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 103 7 (2001) 926-933
27. Mannami T., Konishi M., Baba S., Nishi N., and Terao A. Prevalence of asymptomatic carotid atherosclerotic lesions detected by high-resolution ultrasonography and its relation to cardiovascular risk factors in the general population of a Japanese city: the Suita study. Stroke 28 3 (1997) 518-525
28. Smilde T.J., van den Berkmortel F.W., Boers G.H., Wollersheim H., de Boo T., van Langen H., et al. Carotid and femoral artery wall thickness and stiffness in patients at risk for cardiovascular disease, with special emphasis on hyperhomocysteinemia. Arterioscler Thromb Vasc Biol 18 12 (1998) 1958-1963
29. Bots M.L., Breslau P.J., Briet E., de Bruyn A.M., van Vliet H.H., van den Ouweland F.A., et al. Cardiovascular determinants of carotid artery disease. The Rotterdam elderly study. Hypertension 19 6 Pt 2 (1992) 717-720
30. Burke G.L., Evans G.W., Riley W.A., Sharrett A.R., Howard G., Barnes R.W., et al. Arterial wall thickness is associated with prevalent cardiovascular disease in middle-aged adults. The atherosclerosis risk in communities (ARIC) study. Stroke 26 3 (1995) 386-391
31. Chambless L.E., Heiss G., Folsom A.R., Rosamond W., Szklo M., Sharrett A.R., et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the atherosclerosis risk in communities (ARIC) study, 1987-1993. Am J Epidemiol 146 6 (1997) 483-494
32. Hodis H.N., Mack W.J., LaBree L., Selzer R.H., Liu C.R., Liu C.H., et al. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med 128 4 (1998) 262-269
33. Furberg C.D., Adams H.P., Applegate W.B., Byington R.P., Espeland M.A., Hartwell T., et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic carotid artery progression study (ACAPS) research group. Circulation 90 4 (1994) 1679-1687
34. Smilde T.J., van Wissen S., Wollersheim H., Trip M.D., Kastelein J.J., and Stalenhoef A.F. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 357 9256 (2001) 577-581
35. Nissen S.E., Nicholls S.J., Sipahi I., Libby P., Raichlen J.S., Ballantyne C.M., et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 295 13 (2006) 1556-1565
36. Kapoor A.S., Kanji H., Buckingham J., Devereaux P.J., and McAlister F.A. Strength of evidence for perioperative use of statins to reduce cardiovascular risk: systematic review of controlled studies. BMJ 333 7579 (2006) 1149
37. Durazzo A.E., Machado F.S., Ikeoka D.T., De Bernoche C., Monachini M.C., Puech-Leao P., et al. Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trial. J Vasc Surg 39 5 (2004) 967-975 [discussion: 975-6]
38. Christenson J.T. Preoperative lipid-control with simvastatin reduces the risk of postoperative thrombocytosis and thrombotic complications following CABG. Eur J Cardiothorac Surg 15 4 (1999) 394-399 [discussion: 399-400]
39. Dunkelgrun M., Boersma E., Gemert A.K., van Poorten F., Kalkman C., Schouten O., et al. Abstract 4536: bisoprolol and fluvastatin for the reduction of perioperative cardiac mortality and myocardial infarction in intermediate-risk patients undergoing non-cardiovascular surgery; a randomized controlled trial. Circulation 118 (2008 Oct 28) S906-S907 [18 Meeting Abstracts]
40. Chan Y.C., Cheng S.W., and Irwin M.G. Perioperative use of statins in noncardiac surgery. Vasc Health Risk Manag 4 1 (2008) 75-81
41. Howard-Alpe G., Foex P., and Biccard B. Cardiovascular protection by anti-inflammatory statin therapy. Best Pract Res Clin Anaesthesiol 22 1 (2008) 111-133
42. Fleisher L.A., Beckman J.A., Brown K.A., Calkins H., Chaikof E.L., Fleischmann K.E., et al. ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery) developed in collaboration with the American Society of echocardiography, American Society of nuclear cardiology, Heart Rhythm Society, Society of cardiovascular anesthesiologists, Society for cardiovascular angiography and interventions, Society for vascular medicine and biology, and Society for vascular surgery. J Am Coll Cardiol 50 17 (2007) e159-e242
43. Charlson M., Peterson J., Szatrowski T.P., MacKenzie R., and Gold J. Long-term prognosis after peri-operative cardiac complications. J Clin Epidemiol 47 12 (1994) 1389-1400
44. Poldermans D. Fluvastatin XL use is associated with improved cardiac outcome after major vascular surgery. Results from a randomized placebo-controlled trial: DECREASE III. Available from: (2008). [internet]
45. Schouten O., Hoeks S.E., Welten G.M., Davignon J., Kastelein J.J., Vidakovic R., et al. Effect of statin withdrawal on frequency of cardiac events after vascular surgery. Am J Cardiol 100 2 (2007) 316-320
46. Biccard B.M., Sear J.W., and Foex P. The pharmaco-economics of peri-operative statin therapy. Anaesthesia 60 11 (2005) 1059-1063
47. Schouten O., Kok N.F., Boersma E., Bax J.J., Feringa H.H., Vidakovic R., et al. Effects of statins on renal function after aortic cross clamping during major vascular surgery. Am J Cardiol 97 9 (2006) 1383-1385
48. Welten G.M., Chonchol M., Schouten O., Hoeks S., Bax J.J., van Domburg R.T., et al. Statin use is associated with early recovery of kidney injury after vascular surgery and improved long-term outcome. Nephrol Dial Transplant 23 12 (2008) 3867-3873
49. Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J Vasc Surg 45 4 (2007) 645-654 [discussion: 653-4]
50. Leng G.C., Price J.F., and Jepson R.G. Lipid-lowering for lower limb atherosclerosis. Cochrane Database Syst Rev 2 (2000) CD000123
51. Mondillo S., Ballo P., Barbati R., Guerrini F., Ammaturo T., Agricola E., et al. Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease. Am J Med 114 5 (2003) 359-364
52. Amarenco P., Labreuche J., Lavallee P., and Touboul P.J. Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke 35 12 (2004) 2902-2909
53. Amarenco P., Bogousslavsky J., Callahan A., Goldstein L.B., Hennerici M., Rudolph A.E., et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 355 6 (2006) 549-559
54. Sillesen H., Amarenco P., Hennerici M.G., Callahan A., Goldstein L.B., Zivin J., et al. Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis. A secondary analysis of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) trial. Stroke 39 12 (2008) 3297-3302
55. Baxter B.T., Terrin M.C., and Dalman R.L. Medical management of small abdominal aortic aneurysms. Circulation 117 14 (2008) 1883-1889
56. Abisi S., Burnand K.G., Humphries J., Waltham M., Taylor P., and Smith A. Effect of statins on proteolytic activity in the wall of abdominal aortic aneurysms. Br J Surg 95 3 (2008) 333-337
57. Guessous I., Periard D., Lorenzetti D., Cornuz J., and Ghali W.A. The efficacy of pharmacotherapy for decreasing the expansion rate of abdominal aortic aneurysms: a systematic review and meta-analysis. PLoS ONE 3 3 (2008) e1895
58. Lindholt J.S., Henneberg E.W., Juul S., and Fasting H. Impaired results of a randomised double blinded clinical trial of propranolol versus placebo on the expansion rate of small abdominal aortic aneurysms. Int Angiol 18 1 (1999) 52-57
59. Propranolol for small abdominal aortic aneurysms: results of a randomized trial. J Vasc Surg 35 1 (2002) 72-79
60. Schouten O., van Laanen J.H., Boersma E., Vidakovic R., Feringa H.H., Dunkelgrun M., et al. Statins are associated with a reduced infrarenal abdominal aortic aneurysm growth. Eur J Vasc Endovasc Surg 32 1 (2006) 21-26
61. Sukhija R., Aronow W.S., Sandhu R., Kakar P., and Babu S. Mortality and size of abdominal aortic aneurysm at long-term follow-up of patients not treated surgically and treated with and without statins. Am J Cardiol 97 2 (2006) 279-280
62. Falagas M.E., Makris G.C., Matthaiou D.K., and Rafailidis P.I. Statins for infection and sepsis: a systematic review of the clinical evidence. J Antimicrob Chemother 61 4 (2008) 774-785
63. Almog Y., Shefer A., Novack V., Maimon N., Barski L., Eizinger M., et al. Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation 110 7 (2004) 880-885
64. Martin C.P., Talbert R.L., Burgess D.S., and Peters J.I. Effectiveness of statins in reducing the rate of severe sepsis: a retrospective evaluation. Pharmacotherapy 27 1 (2007) 20-26
65. Schmidt H., Hennen R., Keller A., Russ M., Muller-Werdan U., Werdan K., et al. Association of statin therapy and increased survival in patients with multiple organ dysfunction syndrome. Intensive Care Med 32 8 (2006) 1248-1251
66. Thomsen R.W., Hundborg H.H., Johnsen S.P., Pedersen L., Sorensen H.T., Schonheyder H.C., et al. Statin use and mortality within 180 days after bacteremia: a population-based cohort study. Crit Care Med 34 4 (2006) 1080-1086
67. Kruger P., Fitzsimmons K., Cook D., Jones M., and Nimmo G. Statin therapy is associated with fewer deaths in patients with bacteraemia. Intensive Care Med 32 1 (2006) 75-79
68. Liappis A.P., Kan V.L., Rochester C.G., and Simon G.L. The effect of statins on mortality in patients with bacteremia. Clin Infect Dis 33 8 (2001) 1352-1357
69. Yang K.C., Chien J.Y., Tseng W.K., Hsueh P.R., Yu C.J., and Wu C.C. Statins do not improve short-term survival in an oriental population with sepsis. Am J Emerg Med 25 5 (2007) 494-501
70. Hauer-Jensen M., Fort C., Mehta J.L., and Fink L.M. Influence of statins on postoperative wound complications after inguinal or ventral herniorrhaphy. Hernia 10 1 (2006) 48-52
71. Gao F., Linhartova L., Johnston A.M., and Thickett D.R. Statins and sepsis. Br J Anaesth 100 3 (2008) 288-298
72. Kruger P.S. Re: statins and sepsis. Br J Anaesth 100 6 (2008) 862
73. Statins for the early treatment of sepsis (SETS). Clinical trials identifier NCT 00528580. Available from: .
74. Statin therapy in the treatment of sepsis. Clinical trials identifier NCT 00676897. Available from: .
75. Simvastatin in patients with septic shock. Clinical trials identifier NCT 00450840. Available from: .
76. Effect of rosuvastatin in abdominal sepsis. Clinical trials identifier NCT 00357123. Available from: .
77. Giblin P.A., and Lemieux R.M. LFA-1 as a key regulator of immune function: approaches toward the development of LFA-1-based therapeutics. Curr Pharm Des 12 22 (2006) 2771-2795
78. Weitz-Schmidt G., Welzenbach K., Brinkmann V., Kamata T., Kallen J., Bruns C., et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 7 6 (2001) 687-692
79. Aarons C.B., Cohen P.A., Gower A., Reed K.L., Leeman S.E., Stucchi A.F., et al. Statins (HMG-CoA reductase inhibitors) decrease postoperative adhesions by increasing peritoneal fibrinolytic activity. Ann Surg 245 2 (2007) 176-184
80. Aoki T., Kataoka H., Ishibashi R., Nozaki K., and Hashimoto N. Simvastatin suppresses the progression of experimentally induced cerebral aneurysms in rats. Stroke 39 4 (2008) 1276-1285
81. Gallia G.L., and Tamargo R.J. Leukocyte-endothelial cell interactions in chronic vasospasm after subarachnoid hemorrhage. Neurol Res 28 7 (2006) 750-758
82. Keyrouz S.G., and Diringer M.N. Clinical review: prevention and therapy of vasospasm in subarachnoid hemorrhage. Crit Care 11 4 (2007) 220
83. Sillberg V.A., Wells G.A., and Perry J.J. Do statins improve outcomes and reduce the incidence of vasospasm after aneurysmal subarachnoid hemorrhage: a meta-analysis. Stroke 39 9 (2008) 2622-2626
84. Tseng M.Y., Hutchinson P.J., Czosnyka M., Richards H., Pickard J.D., and Kirkpatrick P.J. Effects of acute pravastatin treatment on intensity of rescue therapy, length of inpatient stay, and 6-month outcome in patients after aneurysmal subarachnoid hemorrhage. Stroke 38 5 (2007) 1545-1550
85. Tseng M.Y., Hutchinson P.J., Turner C.L., Czosnyka M., Richards H., Pickard J.D., et al. Biological effects of acute pravastatin treatment in patients after aneurysmal subarachnoid hemorrhage: a double-blind, placebo-controlled trial. J Neurosurg 107 6 (2007) 1092-1100
86. Kirkpatrick P.J. Simvastatin in aneurysmal subarachnoid haemorrhage (STASH) a multicentre randomised controlled clinical trial. Available from: (2008 Sep 8).
87. Cooper A., Nherera L., Calvert N., O'Flynn N., Turnbull N., Robson J., et al. Clinical guidelines and evidence review for lipid modification: cardiovascular risk assessment and the primary and secondary prevention of cardiovascular disease. National Collaborating Centre for Primary Care and Royal College of General Practitioners (2008), National Institute of Clinical Excellence Guidance